A Phase 2 interventional study of ZD4054 and Pemetrexed in Non Small Cell Lung Cancer and Lung Cancer, sponsored by AstraZeneca. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 93rd largest by enrollment of the 137 interventional ones that give a count, is one of 2 that started in 2008, is one of 38 in phase 2, and was the 27th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 48 · Phase 3 44 · Phase 4 10
First in 2000; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 152 across the 137 interventional studies, 350 across the 67 observational. Of the 123 that completed or were terminated, 45 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
16 of the studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05120349Phase 3AstraZenecaA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | 2027-08-02 |
| NCT05687266Phase 3AstraZenecaPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | 2027-11-01 |
| NCT05456867AstraZenecaA Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia | 2026-11-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZD4054 + Pemetrexed
Drug: ZD4054 · Drug: Pemetrexed
ZD4054 matched placebo + pemetrexed
Drug: Pemetrexed · Drug: Placebo
10mg oral tablet, once daily
Also known as: Zibotentan
500mg2/m IV infusion
Also known as: Alimta
10mg oral tablet, once daily
Time to Death
Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)
Time frame: Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).
Progression-free Survival
Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method
Time frame: Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation
80 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) where the histology was not predominantly of squamous type were recruited between 12th August 2008 and 3rd June 2009.
| Milestone | Placebo + Pemetrexed | ZD4054 + Pemetrexed |
|---|---|---|
| Started | 36 | 30 |
| Completed | 32 | 26 |
| Not completed | 4 | 4 |
| Withdrew: Continuing study treatment | 4 | 4 |
Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)
| Days | Placebo + Pemetrexed | ZD4054 + Pemetrexed |
|---|---|---|
| Time to Death | 193 (27 to 437) | 146 (19 to 427) |
Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method
| Days | Placebo + Pemetrexed | ZD4054 + Pemetrexed |
|---|---|---|
| Progression-free Survival | 87 (27 to 283) | 110 (18 to 303) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Pemetrexed | — | 7/30 (23.3%) | 22/30 (73.3%) |
| ZD4054 + Pemetrexed | — | 4/36 (11.1%) | 20/36 (55.6%) |
| Event | Placebo + Pemetrexed | ZD4054 + Pemetrexed |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/30 | 0/36 |
| Febrile Bone Marrow AplasiaBlood and lymphatic system disorders | 1/30 | 0/36 |
| Right Ventricular FailureCardiac disorders | 1/30 | 0/36 |
| PancreatitisGastrointestinal disorders | 1/30 | 0/36 |
| Upper Gastrointestinal HaemorrhageGastrointestinal disorders | 1/30 | 0/36 |
| Adverse Drug ReactionGeneral disorders | 1/30 | 0/36 |
| AstheniaGeneral disorders | 1/30 | 0/36 |
| Metastases To Central Nervous SystemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/30 | 0/36 |
| Renal FailureRenal and urinary disorders | 1/30 | 0/36 |
| PancytopeniaBlood and lymphatic system disorders | 0/30 | 1/36 |
| Event | Placebo + Pemetrexed | ZD4054 + Pemetrexed |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 8/30 | 7/36 |
| NeutropeniaBlood and lymphatic system disorders | 5/30 | 1/36 |
| NauseaGastrointestinal disorders | 2/30 | 5/36 |
| Oedema PeripheralGeneral disorders | 1/30 | 4/36 |
| Body Temperature IncreasedInfections and infestations | 3/30 | 2/36 |
| Weight DecreasedInfections and infestations | 3/30 | 3/36 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 3/30 | 0/36 |
| Brain Natriuretic Peptide IncreasedInfections and infestations | 0/30 | 3/36 |
| HeadacheNervous system disorders | 1/30 | 3/36 |
| RashSkin and subcutaneous tissue disorders | 1/30 | 3/36 |
| Age Continuous(Years) | Placebo + Pemetrexed | ZD4054 + Pemetrexed | Total |
|---|---|---|---|
| Mean | 56.6 ± 12.06 | 57.5 ± 10.44 | 57 ± 11.25 |
| Sex: Female, Male(Participants) | Placebo + Pemetrexed | ZD4054 + Pemetrexed | Total |
|---|---|---|---|
| Female | 8 | 11 | 19 |
| Male | 28 | 19 | 47 |
The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054
Carcinoma, Non-Small-Cell Lung →